All In Biotech

Investigational drug · Phase 3

TNM001

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Respiratory Syncytial Virus Infections.

Phase 3

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

0 still active

All registered trials

3

Any phase or sponsor naming "TNM001"

First trial start

2023

Sep 11, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TNM001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Respiratory Syncytial Virus Infections

Approved drugs for the same conditions: RSV · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "TNM001" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Respiratory Syncytial Virus Infections

  • GSK · Respiratory Syncytial Virus Infections

  • RSVPreF3 OA vaccinePhase 32 trials

    GSK · Respiratory Syncytial Virus Infections

  • ZiresovirAK0529Phase 32 trials

    Shanghai Ark Biopharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections, Respiratory Synctial Virus Infections

  • GSK · Cardiovascular Disease, Respiratory Syncytial Virus Infections

  • BLB-201PIV5-vectored RSV VaccinePhase 21 trial

    Blue Lake Biotechnology Inc. · Respiratory Syncytial Virus Infections

  • SYH2066Phase 21 trial

    CSPC Ouyi Pharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.